

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2010; month=3; day=11; hr=9; min=26; sec=14; ms=543;]

=====

Application No: 10591047 Version No: 3.0

Input Set:

Output Set:

Started: 2010-03-09 10:28:27.053
Finished: 2010-03-09 10:28:28.809
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 756 ms
Total Warnings: 8
Total Errors: 0
No. of SeqIDs Defined: 8
Actual SeqID Count: 8

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)

SEQUENCE LISTING

<110> GE Healthcare AS
Lovhaug, Dagfinn

<120> Pharmaceutical compounds

<130> PN0411

<140> 10591047

<141> 2010-03-09

<150> NO 20040953

<151> 2004-03-04

<160> 8

<170> PatentIn version 3.4

<210> 1

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> Synthesised peptide

<220>

<221> Misc_feature

<222> (1)..(1)

<223> Any amino acid

<220>

<221> Misc_feature

<222> (2)..(2)

<223> Arg, N-alkylated Arg or a mimetic thereof

<220>

<221> Misc_feature

<222> (8)..(8)

<223> Gly, Phe or an amino acid containing an aromatic or aliphatic side-chain

<220>

<221> Misc_feature

<222> (9)..(9)

<223> Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys

<220>

<221> Misc_feature

<222> (10)..(10)

<223> Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys

<400> 1

Xaa Xaa Val Tyr Ile His Pro Xaa Xaa Xaa

1 5

10

<210> 2
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Angiotensin I sequence

<400> 2

Gly Arg Val Tyr Ile His Pro Phe His Leu
1 5 10

<210> 3
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthesised peptide

<400> 3

Gly Arg Val Tyr Ile His Pro Ile His Leu
1 5 10

<210> 4
<211> 9
<212> PRT
<213> Artificial sequence

<220>
<223> Synthesised peptide

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Amino acid in position 7 is Bip 2-amino-3-biphenyl propionic acid

<400> 4

Arg Val Tyr Ile His Pro Xaa His Leu
1 5

<210> 5
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthesised peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Amino acid in position 8 is Bip 2-amino-3-biphenyl propionic acid

<400> 5

Gly Arg Val Tyr Ile His Pro Xaa His Leu
1 5 10

<210> 6
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthesised peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Amino acid in position 8 is Hph 2-amino-4-phenyl butanoic acid

<400> 6

Gly Arg Val Tyr Ile His Pro Xaa His Leu
1 5 10

<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesised peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Amino acid in position 8 is Phg 2-amino-2-phenyl acetic acid

<400> 7

Gly Arg Val Tyr Ile His Pro Xaa His Leu
1 5 10

<210> 8
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

<223> Angiotensin II sequence

<400> 8

Asp Arg Val Tyr Ile His Pro Phe

1 5